[A20-42] Brigatinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V

Last updated 03.08.2020

Project no.:

Commission awarded on 29.04.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:


Adult patients with ALK-positive advanced NSCLC who have not been previously treated with an ALK inhibitor

Result of dossier assessment:

Patients with brain metastases at the start of treatment: indication of minor added benefit; patients without brain metastases at the start of treatment: hint of minor added benefit


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.